Jan 13, 2022 7:00am EST Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
Jan 10, 2022 7:26am EST Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
Dec 29, 2021 7:00am EST Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
Dec 20, 2021 7:00am EST Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Dec 07, 2021 7:00am EST Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
Nov 26, 2021 7:00am EST Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update
Nov 24, 2021 7:00am EST Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
Nov 23, 2021 7:00am EST Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
